Irish-based Amryt Pharma gets boost for drug in France

Irish-based drug company Amryt Pharma has said its flagship treatment will now be reimbursed by health authorities in France.

The approval for reimbursement will mean that the drug, Lojuxta, which treats a rare condition that can lead to heart attacks, is now available in five key European countries including Britain, Italy, Germany and Spain.

Analysts at Stifel, which is broker to Amryt, estimate that about 100 people in France have homozygous familial hypercholesterolaemia ...